VitaDX
Business Description This technology, based on research carried out by researchers from the Institute of Molecular Sciences in Orsay (ISMO, UMR CNRS and Université Paris-Sud) and practitioners at CHU Bicêtre (AP-HP), aims to diagnose bladder cancer earlier and more reliably.
VitaDX started its first clincal trial in january 2017 and obtained the CE marking for its first.
VitaDX is currently developing a medical software solution for early diagnosis of bladder cancer using fluorescence imaging and machine learning.
Tags Biotechnology,Medical Device,Biotechnology, Hospital, Medical
Website http://vitadx.com/en/
💡 You're a corporate or investor and looking for startups that are innovating in the same market as
VitaDX? We're happy to assist you with our
Startup Sourcing service.